New hope for older leukemia patients: which chemo combo works best?
NCT ID NCT07132684
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tests two different chemotherapy combinations in adults aged 55 to 75 with acute myeloid leukemia (AML) who are healthy enough for strong treatment. One group gets venetoclax plus azacitidine, the other gets standard drugs (daunorubicin or idarubicin plus cytarabine). The goal is to see which approach helps people live longer and achieve remission. About 240 participants will take part across multiple hospitals in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.